Stocks · Healthcare · Biotechnology
Entrada Therapeutics, Inc. TRDA
$5.38 -5.28% Close, Oct 2, 2026 · NASDAQ · Market cap $208.9M
Weak trendExpensive vs sector
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $4.7M, down 94.1% from a year earlier, accelerating from -96.7% a quarter earlier.
- Operating margin narrowed to -3767.1% from -121.0% a year earlier.
- The stock is 66% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 5%
- Revenue growth accelerationTop 25%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 19%
- Gross marginBottom 2%
- Operating marginBottom 8%
- Accruals (lower is better)Top 33%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 10%
- Free-cash-flow yieldBottom 6%
- EBITDA / enterprise valueBottom 5%
- Sales / enterprise valueBottom 14%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 47%
- 6-month returnBottom 2%
- 1-year return vs S&P 500Bottom 37%
- Distance from 52-week highBottom 10%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 38%
- Consecutive EPS beatsTop 25%
- Share of analysts rating BuyBottom 34%
- Upside to consensus price targetTop 25%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 28%
- Maximum drawdown, 3 yearsBottom 39%
- Beta vs S&P 500 (lower is better)Top 37%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -96.7% | -94.1% | ↑ |
| Gross margin | 100.0% | -754.7% | ↓ |
| Operating margin | -121.0% | -3767.1% | ↓ |
| FCF margin | -159.2% | -2867.1% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -94.1% | -96.7% | ↑ | Bottom 5% |
| Gross margin | -754.7% | 100.0% | ↓ | Bottom 2% |
| Operating margin | -3767.1% | -121.0% | ↓ | Bottom 8% |
| Net margin | -3537.7% | -92.3% | ↓ | — |
| Free-cash-flow margin | -2867.1% | -159.2% | ↓ | — |
| Return on invested capital | -62.6% | — | Bottom 19% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -10.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 413.3%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +63.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.31%
- Shareholder yield
- -0.31%
- Share count change, 1 year
- +2.1%
- Share count change, 3-year CAGR
- +8.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 3
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +10.2%
- Average 2-day reaction, last 8
- -5.1%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $14.00
- Target vs current price
- +160.2%
- Analysts with a rating
- 6
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +3.7% | -2.5% | -2.8% | -2.3% | — |
| May 7, 2026 | +10.4% | -57.3% | -54.3% | -56.3% | -54.7% |
| Feb 26, 2026 | +28.8% | +6.8% | +4.3% | +0.6% | -47.3% |
| Nov 6, 2025 | -1.9% | +0.1% | +15.4% | +46.4% | +69.9% |
| Aug 6, 2025 | -20.9% | +2.1% | -11.5% | -8.7% | +18.2% |
| May 8, 2025 | +46.2% | +5.6% | -2.3% | -0.5% | -27.5% |
| Feb 27, 2025 | +104.5% | -0.3% | -12.0% | -17.6% | -36.6% |
| Nov 5, 2024 | +47.8% | +4.8% | +11.9% | +13.5% | -25.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$1.01 | -$1.05 | +3.7% | $898,000 |
| May 7, 2026 | -$0.95 | -$1.06 | +10.4% | $875,000 |
| Feb 26, 2026 | -$0.94 | -$1.32 | +28.8% | $1.3M |
| Nov 6, 2025 | -$1.06 | -$1.04 | -1.9% | $1.6M |
| Aug 6, 2025 | -$1.04 | -$0.86 | -20.9% | $1.9M |
| May 8, 2025 | -$0.42 | -$0.78 | +46.2% | $20.6M |
| Feb 27, 2025 | $0.03 | -$0.66 | +104.5% | $37.4M |
| Nov 5, 2024 | -$0.35 | -$0.67 | +47.8% | $19.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 33.74× | — | — | Bottom 14% |
| Free-cash-flow yield | -64.33% | — | — | Bottom 6% |
| Earnings yield | -73.79% | — | — | Bottom 10% |
P/E over the past five years
Range 5.3× – 22.0× since Mar 31, 2024. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -2.7%
- 200-day average slope (20 days)
- -3.6%
- Distance from 50-day average
- -21.7%
- Distance from 200-day average
- -42.3%
- RSI (14)
- 28.6
- Relative volume
- 1.37×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 69.6%
- Volatility vs own 5-year history
- 47th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.90
- Correlation with S&P 500
- 0.19
- Current drawdown from 1-year high
- -66.4%
- Maximum drawdown, 3 years
- -76.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 17, 2021 | Aug 11, 2025 | -85.7% | 934 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $208.9M
- EPS, diluted (TTM)
- -$3.97
- Revenue (TTM)
- $4.7M
- 52-week range
- $5.17 – $16.45
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $129.0M | $210.8M | $25.4M |
| Gross profit | $0 | $0 | $129.0M | $210.8M | $21.3M |
| Operating income | -$51.1M | -$97.2M | -$3.2M | $47.0M | -$156.0M |
| Net income | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
| EPS (diluted) | -$1.60 | -$2.79 | -$0.20 | $1.68 | -$3.47 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.6M | $37.4M | $20.6M | $1.9M | $1.6M | $1.3M | $875,000 | $898,000 |
| Net income | -$14.0M | $1.1M | -$17.3M | -$43.1M | -$44.1M | -$39.2M | -$39.7M | -$42.8M |
| EPS (diluted) | -$0.35 | $0.03 | -$0.42 | -$1.04 | -$1.06 | -$0.95 | -$0.95 | -$1.01 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$50.9M | -$93.8M | $139.8M | -$41.6M | -$128.5M |
| Capital expenditure | -$4.6M | -$2.9M | -$5.6M | -$3.2M | -$1.0M |
| Free cash flow | -$55.4M | -$96.7M | $134.2M | -$44.7M | -$129.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $190.7M | $479,000 | $19.4M | $99.6M | $887,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $223.0M
- Total assets
- $298.9M
- Total liabilities
- $65.5M
- Total debt
- $48.5M
- Net debt
- -$50.7M
- Shareholders’ equity
- $233.4M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 2,744,145
- Days to cover
- 8.06
- Change vs previous report
- +17.0%
FINRA short interest, settlement date Sep 15, 2026.